Academic literature on the topic 'PEMO-Q'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'PEMO-Q.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "PEMO-Q"
1
Huber, R., and B. Kollmeier. "PEMO-Q—A New Method for Objective Audio Quality Assessment Using a Model of Auditory Perception." IEEE Transactions on Audio, Speech and Language Processing 14, no. 6 (November 2006): 1902–11. http://dx.doi.org/10.1109/tasl.2006.883259.
Full text
2
Shahda, Safi, Anne M. Noonan, Tanios S. Bekaii-Saab, Bert H. O'Neil, Amikar Sehdev, Walid Labib Shaib, Paul R. Helft, et al. "A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 3541. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.3541.
Full textAbstract:
3541 Background: Pembrolizumab (PEM) has activity in patients with deficient mismatch repair (dMMR) colorectal cancer (CRC). Oxaliplatin (OX) and 5FU lead to immunogenic cell death and increased antigen presentation. We hypothesized that combining mFOLFOX6 and PEM may enhance immunogenic cell death and improve outcome in patients with CRC irrespective of MMR status. Methods: Subjects ≥18 years old with untreated, unresectable CRC were assigned to a single arm study. The study had a safety run in cohort of six patients (OX 85 mg/m2, leucovorin 400 mg/m2, 5FU 400 mg/m2, 5FU infusion 2400 mg/m2over 46 hours) and PEM 200 mg Q 3 weeks, followed by a phase II cohort. The primary objective was median progression free survival (mPFS), with secondary objectives: safety and toxicity per CTCAE V4.03, median overall survival, response rate, immune related response, disease control rate, and molecular correlates. Results: Between 4/2015 and 9/2016, 30 subjects were enrolled with following characteristics: 11 female, 26 Caucasian, median age: 45 years (25-75), 3 with dMMR, 22 MMR-proficient, and 5 with no available data. During the safety run in, 2 patients had G3 febrile neutropenia (FN) and 1 G4 neutropenia. The data safety monitoring committee recommended dose reduction of mFOLFOX6 to OX 68 mg/m2, leucovorin 400 mg/m2, 5FU of 320 mg/m2, 5FU infusion of 1920 mg/m2over 46 hours and PEM 200 mg Q 3 weeks. At the data cut off (12/29/16), median follow up was 24 weeks (10-66) and 27 patients remained on study. Rate of G3/4 toxicity associated with FOLFOX/PEM and PEM alone was 36.7% and 13.2%, respectively. No further FN was observed. No grade 5 toxicity was seen on study. Best response was recorded as: 1 complete response, 15 partial response (CR +PR = 53%), and 14 stable disease, with 100% DCR at 8 weeks. One patient with dMMR had resection after 2 months of therapy with complete pathologic response. MPFS has not been reached (95% CI: 5.5 months, NR). Conclusions: Based on these preliminary results, PEM/mFOLFOX6 has acceptable toxicity though demonstrated a suggestion of increased neutropenia in the initial cohort. Clinical activity was seen in patients with untreated advanced CRC including those with proficient MMR. Clinical trial information: NCT02375672.
3
Nair, Amruta, T. Balasaravanan, Sunil Jadhav, Vysakh Mohan, and Chethan Kumar. "Harnessing the antibacterial activity of Quercus infectoria and Phyllanthus emblica against antibiotic-resistant Salmonella Typhi and Salmonella Enteritidis of poultry origin." July-2020 13, no. 7 (2020): 1388–96. http://dx.doi.org/10.14202/vetworld.2020.1388-1396.
Full textAbstract:
Background and Aim: In a scenario of the ineffectiveness of the current drugs against antibiotic-resistant pathogens, the herbal extracts can serve as an alternative remedy. This study appraises the antibacterial potency of Quercus infectoria (gall), Phyllanthus emblica (fruit) individually and synergistically against antimicrobial-resistant (AMR) Salmonella Typhi and Salmonella Enteritidis in a time and dose-dependent manner. Further, the antibacterial phytocompounds were identified employing gas chromatography-mass spectrometry (GC-MS). Materials and Methods: Preliminary antibacterial activity of the plant extracts was assessed using the agar disk diffusion method. In vitro evaluations of Q. infectoria methanolic extract (QIME) and P. emblica methanolic extract (PEME) against S. Typhi and S. Enteritidis were carried out using plate count method. Results: QIME and PEME at a dose rate of 50 mg/ml and 25 mg/ml, respectively, had a complete bactericidal effect on AMR S. Typhi and S. Enteritidis whereas 10 log10 CFU/ml of exponential growth was seen in untreated control groups. At the lower concentrations, QIME and PEME had a significant bacteriostatic effect (3-6 log10 reduction of the test isolates). The synergistic antibacterial effect obtained from the combination of these two plant extracts at 12.5 mg/ml was superior (p<0.001) than the individual treatments. Phytochemical profiling indicated the presence of tannins, flavonoids, saponins, and terpenoids in both the plant extracts. GC-MS analysis of QIME and PEME revealed the presence of 16 and 15 antibacterial phytocompounds, respectively. Further 1, 2, 3 Benzenetriol was found as the prominent active principle. Conclusion: The findings validate that QIME and PEME are potential antibacterial agents against AMR S. Typhi, S. Enteritidis and can play a promising role in antimicrobial packaging, poultry feed additives and can also serve as a platform for formulating effective phytotherapeutics.
4
Garland, L. L., L. Cranmer, G. Gerstner, R. Walker, Y. Obregon, and S. Ebbinghaus. "Phase I dose escalation trial of biweekly pemetrexed in combination with docetaxel in advanced solid tumors." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 13019. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.13019.
Full textAbstract:
13019 Background: Pemetrexed (PEM) and docetaxel (DOC) are cytotoxic agents with a broad range of activity in solid tumors and relatively non-overlapping toxicities. We are conducting a single site dose escalation trial of biweekly dosing of PEM + DOC in advanced solid tumor patients (pts) to determine the maximum tolerated dose (MTD), dose limiting toxicities (DLTs), and preliminary antitumor activity for the combination. Eligible pts have had 0–1 prior therapies, a performance status of 0–1, and creatinine clearance of =45 ml/min. Methods: Escalating doses of PEM (10 min infusion, d1 and 15) and DOC (1 hr infusion, d1 and 15) are administered q 28 days. Pretreatment vitamin supplementation consists of 1 mg IM vitamin B12 repeated q 9 weeks and daily oral folate 350–1,000 mcg. DLT is defined as grade 4 neutropenia =5 days, febrile neutropenia, grade 4 thrombocytopenia, or grade 3–4 non-hematological toxicity in cycle 1. Results: To date, 12 pts ages 40–70 have been enrolled at 3 dose levels. Tumor types (N pts) include leiomyosarcoma (3); schwannoma (1); synovial sarcoma (1); transitional cell carcinoma of the bladder (1) and non-small cell lung carcinoma (NSCLC) (6). One patient was withdrawn for early progressive disease. Grade 3/4 treatment-emergent toxicities for 11 pts include neutropenia (3), anemia (1), mucositis (1), hyperglycemia (1), anorexia (1), weight loss (1), hyponatremia (1), pain (1), dehydration (1), fatigue (1), and thromboembolism (1). In addition, one pt had grade 5 pneumonitis during cycle 3. Dose level 3 has been expanded due to DLT in 1 pt. Antitumor activity for 11 evaluable pts includes 2 confirmed partial responses (by RECIST) in uterine leiomyosarcoma after adjuvant AIM therapy and pretreated NSCLC; stable disease in 5 pts; and progressive disease in 4 pts. Conclusion: Biweekly dosing of PEM + DOC is feasible and shows activity in a number of advanced solid tumors. The MTD has not been reached. *Pt with early progression replaced [Table: see text] No significant financial relationships to disclose.
5
Biswas, Tithi, Kylie H. Kang, Rohin Gawdi, David Bajor, Mitchell Machtay, Charu Jindal, and Jimmy T. Efird. "Using the Systemic Immune-Inflammation Index (SII) as a Mid-Treatment Marker for Survival among Patients with Stage-III Locally Advanced Non-Small Cell Lung Cancer (NSCLC)." International Journal of Environmental Research and Public Health 17, no. 21 (October 30, 2020): 7995. http://dx.doi.org/10.3390/ijerph17217995.
Full textAbstract:
The Systemic Immune-Inflammation Index (SII) is an important marker of immune function, defined as the product of neutrophil-to-lymphocyte ratio (NLR) and platelet count (P). Higher baseline SII levels have been associated with improved survival in various types of cancers, including lung cancer. Data were obtained from PROCLAIM, a randomized phase III trial comparing two different chemotherapy regimens pemetrexed + cisplatin (PEM) vs. etoposide + cisplatin (ETO), in combination with radiotherapy (RT) for the treatment of stage III non-squamous non-small cell lung cancer (NSCLC). We aimed to determine if SII measured at the mid-treatment window for RT (weeks 3–4) is a significant predictor of survival, and if the effect of PEM vs. ETO differs by quartile (Q) level of SII. Hazard-ratios (HR) for survival were estimated using a proportional hazards model, accounting for the underlying correlated structure of the data. A total of 548 patients were included in our analysis. The median age at baseline was 59 years. Patients were followed for a median of 24 months. Adjusting for age, body mass index, sex, race, and chemotherapy regimen, SII was a significant mid-treatment predictor of both overall (adjusted HR (aHR) = 1.6, p < 0.0001; OS) and progression-free (aHR = 1.3, p = 0.0072; PFS) survival. Among patients with mid-RT SII values above the median (6.8), those receiving PEM (vs. ETO) had superior OS (p = 0.0002) and PFS (p = 0.0002). Our secondary analysis suggests that SII is an informative mid-treatment marker of OS and PFS in locally advanced non-squamous NSCLC.
6
Osborne, Wendy, Maria Marzolini, Eleni Tholouli, Aravind Ramakrishnan, Carlos R. Bachier, Peter A. McSweeney, David Irvine, et al. "Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): 8001. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.8001.
Full textAbstract:
8001 Background: CD19 directed CAR T cells are effective in patients with r/r DLBCL, however relapses due to CD19 loss or PDL1 upregulation are common. In this study, we evaluate the safety and efficacy of AUTO3, a CAR T targeting CD19/22 with limited duration of PD-1 blockade. Methods: We constructed a bicistronic retroviral vector encoding both an anti-CD19 (OX40 co-stim) and an anti-CD22 (41BB co-stim) CAR with humanized binders. The cell product was manufactured in a semi-automated and closed process using CliniMACS Prodigy. Patients (≥ 18 years) with r/r DLBCL (NOS) or transformed (tDLBCL); ECOG <2, adequate organ function are eligible. Lymphodepletion was Flu/Cy prior to AUTO3. Bridging therapy was allowed. The three dose levels explored are 50, 150, and 450 x 10^6 CAR T cells. Patients received AUTO3 alone, or with 3 doses of pembrolizumab (pem) 200 mg q 3 wks starting on D14 (regimen A), or with a single dose of pem 200 mg on D-1 (regimen B). The primary endpoint is frequency of DLTs and grade (G) 3-5 adverse events (AE) and secondary endpoints included ORR, CRR, and biomarkers. Results: As of Jan 21, 2020, 28 patients underwent leukapheresis, 27 successfully manufactured, 1 being manufactured, and 19 patients treated with AUTO3. The median age was 57 (28 - 71) and median number of prior therapies was 3 (2 - 10). 89% had refractory disease, 74% were DLBCL NOS, and 26% were tDLBCL. Dose escalation from 50 to 450 x 106 cells with pem regimen A and B have been completed without DLTs. G > 3 treatment emergent AEs that occurred > 15% were neutropenia (89%), thrombocytopenia (58%), anemia (47%), febrile neutropenia (16%), and hypophosphataemia (16%). Across all dose levels, there were 0% sCRS with primary infusion and 5% severe neurotoxicity (sNT) (1/19), which resolved. There were no cases of sCRS and no neurotoxicity of any grade at > 50 x 106 cells. Eighteen patients were evaluable for efficacy. Among the 11 treated at dose > 50 x 106, the ORR and CRR were 64% and 55%, and all CRs are ongoing (1-12 mth). Two out of 3 patients achieved CR at 450 x 106 cells on pem regimen B. Additional patients and longer follow up, as well as biomarkers, will be presented. Conclusions: AUTO3 at > 50 x 106 CAR T cells with pembrolizumab induces CRs without severe CRS or neurotoxicities of any grade. Clinical trial information: NCT03287817 .
7
Manzano, M., R. Rueda, J. H. Baxter, and J. M. Lopez-Pedrosa. "Preventive effect on N-acetyl-glutamine (NAQ) vs glutamine (Q) on intestinal dysfunction induced by protein-energy malnutrition (PEM) in pigs." Clinical Nutrition 22 (August 2003): S43—S44. http://dx.doi.org/10.1016/s0261-5614(03)80162-0.
Full text
8
Amir, Nyak. "PENGEMBANGAN ALAT UKUR KECEMASAN OLAHRAGA." Jurnal Penelitian dan Evaluasi Pendidikan 16, no. 1 (January 14, 2013): 325–47. http://dx.doi.org/10.21831/pep.v16i1.1120.
Full textAbstract:
Tujuan penelitian ini adalah mengembangkan alat ukur yang memiliki validitas dan reliabilitas yang baik dan dapat diterapkan sesuai kondisi di Indonesia. Subjek penelitian (N=406) adalah seluruh atlet sepakbola pemula Kota Banda Aceh. Metode pengembangan alat ukur ini dilakukan dengan dua kegiatan, yaitu: adaptasi instrumen, dan pengumpulan butir baru melalui item pool dan screening of item pool (Q-sort). Selanjutnya alat ukur ini diujicobakan melalui dua tahap, yakni uji coba tahap pertama dilakukan pada 406 atlet klub sepakbola pemula, dan uji coba tahap kedua dilakukan pada 1000 atlet klub sepakbola Provinsi Aceh. Data dianalisis melalui pem-buktian validitas dan estimasi reliabilitas. Hasil penelitian menunjukkan bahwa validitas berada pada kategori baik, dan reliabilitas skala kecemasan pada kategori cukup, dan skala kecemasan olahraga yang terdiri atas 4 faktor dan 35 butir pernyataan ini dapat dipakai untuk mengukur kecemasan olahraga.Kata kunci: pengembangan, alat ukur, kecemasan olahraga______________________________________________________________SPORTS DEVELOPMENT TOOLS MEASURING ANXIETYAbstract The aim of this research is to develop standardized instrument with a good validity and reliability to measure sport anxiety which is suitable to local conditions in Indonesia. Subjects of the research were (N =406) beginner soccer players from Banda Aceh Municipality. The development of this measurement tool was conducted through two activities, namely instrument adaptation, and collection of new items through item pooling and screening of the item pool (Q-sort). Then the instrument was validated throught two phases, firstly on 406 beginner soccer players, and secondly, on 1000 soccer players from Aceh Province. Data were analysed through validity and reliability testing and factor analysis. Results show either the validity or the reliability level of anxiety scale was high enough, and that the sport anxiety scale comprising four factors and 35 items could be used to measure sport anxiety.Keywords: development, measurement tool, sport anxiety
9
Cheng, Fengdong, Hongwei Wang, Alfonso Suarez, Pedro Horna, Said Sebti, and Eduardo M. Sotomayor. "Cucurbitacins, a Family of Natural Compounds That Effectively Disrupt Stat3 Signaling in Antigen-Presenting Cells (APCs) Are Promising Agents To Overcome Tumor-Induced CD4+ T-Cell Tolerance." Blood 106, no. 11 (November 16, 2005): 1485. http://dx.doi.org/10.1182/blood.v106.11.1485.1485.
Full textAbstract:
Abstract Signal transducer and activator of transcription 3 (Stat3) is a key mediator of several cytokines and growth factors signaling pathways. On myeloid cells, activation of Stat3 to its phosphorylated form (pStat3) has been shown to negatively regulate inflammatory responses. Recently, we have unambiguously demonstrated that Stat3 signaling in APCs also play a central role in the decision leading to immune activation versus immune tolerance of antigen-specific T-cells1. In spite of these advances, there is however a paucity of therapeutic strategies targeting this signaling pathway in immune cells. Using a high throughput cytoblot screening for phospho-Stat3 inhibition, we have recently identified a family of natural compounds known as Cucurbitacins that effectively disrupt Stat3 signaling at different levels2. Three compounds have been identified, Cucurbitacin A (CuA) that inhibits phospho-JAK-2, Cucurbitacin I (CuI) a dual inhibitor of p-JAK2 and p-Stat3 and Cucurbitacin Q (CuQ) a selective inhibitor of p-Stat3. In vitro treatment of peritoneal elicited macrophages (PEM) and bone marrow-derived dendritic cells (DCs) with increasing concentrations of CuA or CuI resulted in inhibition of p-Stat3 and enhanced antigen presentation to naive CD4+ T cells specific for a MHC class II restricted epitope of influenza hemagglutinin (HA). Indeed, these clonotypic T cells displayed increased antigen-specific proliferation and IL-2 production as compared to clonotypic T cells encountering cognate antigen on untreated APCs. Furthermore, unlike untreated PEM or DCs, which are unable to trigger IFN-gamma production by CD4+ T-cells, Cucurbitacin-treated APCs efficiently trigger the production of this cytokine by naïve CD4+ T-cells in response to cognate antigen. Given the above results, we explored next whether inhibition of Stat3 signaling in B-cell lymphomas by Cucurbitacins might increase the intrinsic antigen-presenting capabilities of these malignant B-cells. Reminiscent of our findings with bone marrow derived APCs, Cucurbitacin-treated A20 lymphoma cells also display enhanced antigen-presenting cell function leading to increased proliferation, IL-2 and IFN-gamma by naive antigen-specific CD4+ T-cells. More importantly, tolerant CD4+ T-cells (isolated from lymphoma bearing mice) exposed to Cucurbitacin-treated A20 B-cells regained their ability to proliferate and produce significant amounts of IL-2 and IFN-gamma in response to cognate antigen stimulation. Taken together, the ability of Cucurbitacins to inhibit p-Stat3 in normal APCs as well as in malignant B-cells make these natural compounds a promising agents to overcome the remarkable barrier that tolerance to tumor antigens has imposed to cancer immunotherapeutic strategies.
10
El-Khoueiry, Anthony B., Richard D. Kim, William P. Harris, Max W. Sung, Dirk Waldschmidt, Syma Iqbal, Xiaojing (Amily) Zhang, Keiko Nakajima, and Peter R. Galle. "Phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC)." Journal of Clinical Oncology 38, no. 4_suppl (February 1, 2020): 564. http://dx.doi.org/10.1200/jco.2020.38.4_suppl.564.
Full textAbstract:
564 Background: REG is a multikinase inhibitor with immunomodulatory activity and PEMBRO is an anti-PD-1 monoclonal antibody. Both are approved as monotherapy for patients (pts) with HCC previously treated with sorafenib. Based on their potential synergistic effects, we conducted a phase 1b study of REG plus PEMBRO for first-line treatment of advanced HCC. Methods: This is an ongoing, open-label, dose-escalation study in pts with advanced HCC who had no prior systemic therapy. In the first cohort, pts received REG 120 mg/day PO for 3 weeks on/1 week off plus PEMBRO 200 mg IV q 3 weeks. In later cohorts, the REG dose could be escalated (160 mg) or reduced (80 mg) based on the modified toxicity probability interval design; the PEMBRO dose is fixed. The primary objective is safety and tolerability. Secondary objectives are to define the maximum tolerated dose (MTD) and recommended phase 2 dose, and to assess antitumor activity. Results: As of August 23, 2019, 29 pts have been treated at the REG 120 mg level. Median age is 65 years (range 32–81); 41%/55% of pts are BCLC stage B/C; 100% are Child–Pugh A; ECOG status 0/1 is 72%/28%. Dose-limiting toxicities occurred in 4/18 evaluable pts: grade (Gr) 3 increased ALT/AST with Gr 2 increased bilirubin (n = 2); Gr 3 rash (n = 2). The MTD of REG in the combination was 120 mg. Most common Gr 3 or 4 treatment-emergent adverse events (TEAEs) are shown (n = 29). There were no Gr 5 TEAEs. 59%/31% of pts had REG/PEMRO-related Gr 3 or 4 TEAEs. Dose modifications (reductions or interruptions) of REG/PEMBRO for drug-related TEAEs occurred in 59%/31% of pts. Of 23 evaluable pts, 7 (30%) had a partial response (PR) and 14 (61%) had stable disease (RECIST v1.1); 1 additional pt had PR by mRECIST. Conclusions: The combination of REG plus PEMBRO for first-line treatment of advanced HCC showed no unexpected safety signals and encouraging antitumor activity. Accrual is continuing at REG 120 mg dose and an expansion cohort evaluating REG 80 mg plus PEMBRO is planned. Clinical trial information: NCT03347292. [Table: see text]
Dissertations / Theses on the topic "PEMO-Q"
1
Peloušek, Tomáš. "Simulace zkreslení zvukového signálu v percepčním zvukovém kodéru." Master's thesis, Vysoké učení technické v Brně. Fakulta elektrotechniky a komunikačních technologií, 2021. http://www.nusl.cz/ntk/nusl-442567.
Full textAbstract:
This thesis deals with the issue of the creation of a programme that would simulate the distortion that appears during the process of lossy audio coding. As the environment for the creation, the MATLAB programming language has been chosen. An encoder, which changes the subjective signal quality according to customer preferences for the bitrate, has been created as a practical part of this thesis. Its function is based on a dynamic bit allocation technique and includes an optional window switching algorithm. The theoretical background for the creation of the programme consists of an explanation of the main principles of lossy coding with emphasis on MPEG1 layer 3 operating principles. The practical chapter describes how the created programme and its parts work, and it includes results of the run quality testing. The testing was conducted using the objective assessment method PEMO-Q, and consisted of comparing the objective quality of the programme’s outputs to the quality of samples on which a regular MP3 encoder with identical settings was used.
Book chapters on the topic "PEMO-Q"
1
Jabari, Farkhondeh, Heresh Seyedia, Sajad Najafi Ravadanegh, and Behnam Mohammadi Ivatloo. "Stochastic Contingency Analysis Based on Voltage Stability Assessment in Islanded Power System Considering Load Uncertainty Using MCS and k-PEM." In Advances in Computer and Electrical Engineering, 12–36. IGI Global, 2016. http://dx.doi.org/10.4018/978-1-4666-9911-3.ch002.
Full textAbstract:
Increased electricity demands and economic operation of large power systems in a deregulated environment with a limited investment in transmission expansion planning causes interconnected power grids to be operated closer to their stability limits. Meanwhile, the loads uncertainty will affect the static and dynamic stabilities. Therefore, if there is no emergency corrective control in time, occurrence of wide area contingency may lead to the catastrophic cascading outages. Studies show that many wide area blackouts which led to massive economic losses may have been prevented by a fast feasible controlled islanding decision making. This chapter introduces a novel computationally efficient approach for separating of bulk power system into several stable sections following a severe disturbance. The splitting strategy reduces the large initial search space to an interface boundary network considering coherency of synchronous generators and network graph simplification. Then, a novel islanding scenario generator algorithm denoted as BEM (Backward Elimination Method) based on PMEAs (Primary Maximum Expansion Areas) has been applied to generate all proper islanding solutions in the simplified network graph. The PPF (Probabilistic Power Flow) based on Newton-Raphson method and Q-V modal analysis has been used to evaluate the steady-state stability of created islands in each generated scenario. BICA (Binary Imperialistic Competitive Algorithm) has then been applied to minimize total load-generation mismatch considering integrity, voltage permitted range and steady-state voltage stability constraints. The best solution has then been applied to split the entire power network. A novel stochastic contingency analysis of islands based on PSVI (Probability of Static Voltage Instability) using MCS (Monte Carlo Simulation) and k-PEM (k-Point Estimate Method) have been proposed to identify the critical PQ buses and severe contingencies. In these approaches, the ITM (Inverse Transform Method) has been used to model uncertain loads with normal probability distribution function in optimal islanded power system. The robustness, effectiveness and capability of the proposed approaches have been validated on the New England 39-bus standard power system.
Conference papers on the topic "PEMO-Q"
1
Hatti, M., M. Tioursi, and W. Nouibat. "Notice of Violation of IEEE Publication Principles: A Q-Newton Method Neural Network Model for PEM Fuel Cells." In 2006 4th IEEE International Conference on Industrial Informatics. IEEE, 2006. http://dx.doi.org/10.1109/indin.2006.275856.
Full text
2
Hatti, M., M. Tioursi, and W. Nouibat. "Notice of Violation of IEEE Publication Principles: A Q-Newton Method Neural Network Model for PEM Fuel Cells." In 2006 First International Symposium on Environment Identities and Mediterranean Area. IEEE, 2006. http://dx.doi.org/10.1109/iseima.2006.344946.
Full text